Eugia Pharma receives USFDA Approval for Dasatinib Tablets
Eugia Pharma receives USFDA Approval for Dasatinib Tablets

Eugia Pharma receives USFDA Approval for Dasatinib Tablets

The company has a market cap of over Rs 70,000 crore and the stock is up by 23 per cent from its 52-week low of Rs 994.35 per share.

DSIJ Intelligence-1 Article rating: 5.0

The company has a market cap of over Rs 70,000 crore and the stock is up by 23 per cent from its 52-week low of Rs 994.35 per share. 

Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP
Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP

Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP

Aurobindo Pharma Limited announced obtaining the last approval from the US Food & Drug Administration (USFDA) for Rivaroxaban Tablets USP, 2.5 mg.

DSIJ Intelligence-1 Article rating: 5.0

The biosimilars division alongside niche product development represents Aurobindo Pharma's main focus areas where its 1500 scientists dedicate their efforts.

Medical Equipment & Supplies Expands Global Reach in Medical Devices; Secures USFDA Registration
Medical Equipment & Supplies Expands Global Reach in Medical Devices; Secures USFDA Registration

Medical Equipment & Supplies Expands Global Reach in Medical Devices; Secures USFDA Registration

Company's products are available both online, through its proprietary store and major e-commerce platforms, and offline, with a presence in over 22,000 retail touchpoints across 460+ towns in India.

DSIJ Intelligence-1 Article rating: 5.0

The company's wholly-owned subsidiary, Nureca Technologies Pvt Ltd, specializes in manufacturing medical devices with an annual capacity of 8 lakh units.

Pharma Company Has Received Final Approval From United States Food and Drug Administration For Abbreviated New Drug Application
Pharma Company Has Received Final Approval From United States Food and Drug Administration For Abbreviated New Drug Application

Pharma Company Has Received Final Approval From United States Food and Drug Administration For Abbreviated New Drug Application

The company has a market cap of over Rs 1 lakh crore and the stock is up by 13 per cent from its 52-week low of Rs 1,310.05 per share.

DSIJ Intelligence-1 Article rating: 4.7

The company has a market cap of over Rs 1 lakh crore and the stock is up by 13 per cent from its 52-week low of Rs 1,310.05 per share.

Multibagger Pharma Stock Rises Nearly 3 Per Cent After US FDA Observations on Telangana Facility
Multibagger Pharma Stock Rises Nearly 3 Per Cent After US FDA Observations on Telangana Facility

Multibagger Pharma Stock Rises Nearly 3 Per Cent After US FDA Observations on Telangana Facility

The inspection, conducted between December 9 and December 17, 2024, resulted in two procedural observations from the US FDA.

DSIJ Intelligence Article rating: 4.3

The facility in question, Unit-V, is an active pharmaceutical ingredient (API) manufacturing site operated by Apitoria Pharma Private Ltd, a wholly owned subsidiary of Aurobindo Pharma, located in Pashamylaram Village, Telangana.

 

Indian Pharma Company Scores Major USFDA Approval for Game-Changing Capsule, Plans 5+ New Product Launches!
Indian Pharma Company Scores Major USFDA Approval for Game-Changing Capsule, Plans 5+ New Product Launches!

Indian Pharma Company Scores Major USFDA Approval for Game-Changing Capsule, Plans 5+ New Product Launches!

With the USFDA's green light, the Indian pharmaceutical company is poised to expand its product portfolio and strengthen its global presence

DSIJ Intelligence Article rating: 5.0

With the USFDA's green light, the Indian pharmaceutical company is poised to expand its product portfolio and strengthen its global presence

This pharma company's shares surged to a new 52-week high after receiving final approval from the USFDA.
This pharma company's shares surged to a new 52-week high after receiving final approval from the USFDA.

This pharma company's shares surged to a new 52-week high after receiving final approval from the USFDA.

The share has delivered over 95 per cent returns in the past year, transforming into a multi-bagger with over 260 per cent returns in the last two years.

DSIJ Intelligence Article rating: 3.7

The share has delivered over 95 per cent returns in the past year, transforming into a multi-bagger with over 260 per cent returns in the last two years.

This pharma company stock went 8 per cent high, do you own it?
This pharma company stock went 8 per cent high, do you own it?

This pharma company stock went 8 per cent high, do you own it?

With its shares up 8 per cent, the Indian multinational pharmaceutical company posted a net profit of Rs 130 crore in the second quarter, while its turnover increased to Rs 4,145 crore.

DSIJ Intelligence-1 Article rating: 5.0

This pharma company stock went 8 per cent high, do you own it?                                                                                                                                                                                                       With its shares up 8 per cent, the Indian multinational pharmaceutical company posted a net profit of Rs 130 crore in the second quarter, while its turnover increased to Rs 4,145 crore.

Heavy buying seen in these small-caps that hit fresh 52 week high on August 18!
Heavy buying seen in these small-caps that hit fresh 52 week high on August 18!

Heavy buying seen in these small-caps that hit fresh 52 week high on August 18!

On BSE, 265 stocks have hit their upper circuits whereas 131 stocks touched their lower circuits.  

DSIJ Intelligence Article rating: 4.2

At 2.30 pm on Thursday, the markets were seen recovering from the day’s low as Asia- Pacific markets tumbled following the overnight cooling off of the most recent Wall Street rise.  

RSS
12

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR